Drugs / CKD-385
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04906785 | Jun → Jul 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04906798 | Jun → Jul 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04678388 | Oct → Dec 2020 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04651881 | Oct → Dec 2020 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04075643 | Sep 2019 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04083846 | Sep → Oct 2019 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04083872 | Sep → Oct 2019 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03748212 | Oct → Dec 2018 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-385 | “Reference drug: D744 Test drug: CKD-385 64 mg formulation I Pharmacokinetic blood samples are collected up to 48 hrs.” NCT04083872 ↗7“Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions” NCT04678388 ↗ “CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition” NCT04083846 ↗ “Reference drug: D935 Test drug: CKD-385” NCT04075643 ↗ “CKD-385 64 mg formulation I (878mg)” NCT04651881 ↗ |
| Route | Oral | “single oral administration under fed condition” NCT03748212 ↗ |